FDA reviewers back extrapolation for Amgen's biosimilar Humira

FDA reviewers concluded the "totality of the evidence" support the biosimilarity of ABP 501 from Amgen Inc. (NASDAQ:AMGN) to Humira adalimumab from AbbVie Inc. (NYSE:ABBV), its U.S.-licensed reference product. In briefing documents released ahead of

Read the full 352 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE